# iAP20 Rec'd PCT/PTO 11 MAY 2006

Practitioner's Docket No. 700953-53676

### IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date	
PCT/US2004/038643	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)	

TITLE OF INVENTION:

CUSTOM VECTORS FOR TREATING AND

PREVENTING PANCREATIC CANCER

APPLICANT FOR DO/US/RO: THERION BIOLOGICS CORPORATION, et al.

CI	ERTIFICATE OF MAILING			
I hereby certify that this corn	respondence, on the date shown below, is being			
deposited with the United St	tates Postal Service with sufficient postage as Express			
	Mail Label No. EV 653003274 US in an envelope addressed to MAIL STOP PCT,			
	P. O. Box 1450, Atexandria, VA 2/313-1/50.			
Date: May 11, 2006	Signature			
	Linda M. Ginsberg			

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

## INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1 and C1-C4 cited in the attached Forms PTO/SB/08a and b.

# In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed: (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or (2) within three months of the mailing date of the PCT International Search Report; or

Number

10/579025

(12.11.2003)

IN THE UNITED STATES R International Filing Date **International Earliest Priority Date International Application** 12 November 2003 PCT/US2004/038643 12 November 2004

TITLE OF INVENTION:		CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER		
APPLICANT FOR DO/US/RO:				
	(3)	after the period defined in (1) but before the mailing date of a <b>Final Rejection</b> or <b>Notice of Allowance</b> , and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or		
	(4)	after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.		
<u>X</u>	A copy	of the International Search Report is enclosed herewith.		
	It is res	ectfully requested that each of the documents shown on the attached		
form(s) PTC		PTO/SB/08a and b be made of record in this application.		
	Copies of these documents (CHECK ONE):			
X are enclosed		losed herewith; or		
	have been cited in the parent application, and are thus not being resubmitted herein.			
<u>X</u>	Pursuant to 37 C.F.R. §1.98, copies of issued U.S. patents listed on the attached form PTO/SB/08, if any, are no longer required and therefore are not enclosed. These documents can be found in the U.S. PTO issued patents database.			

(12.11.2004)

# FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: May 11, 2006

Respectfully submitted,

Ronald I. Eisenstein (Reg. No. 30,628)

Leena H. Karttunen (L0207) NIXON PEABODY LLP

100 Summer Street Boston, MA 02110-2131

(617) 345-6054

# IAP20 Rec'd PCT/PTO 11 MAY 2006

Complete if Known

To be assumed Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE 12 November 2004 I.A. Filing Date STATEMENT BY APPLICANT Dennis L. Panicali First Named Inventor (use as many sheets as necessary) To be assigned Art Unit To be assigned Examiner Name Sheet 1 of 2 Attorney Docket Number 700953-53676

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	U.S. Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear		
		110 6 527 552	03-272003	MINION et al.			
	+	US-6,537,552					
	<del> </del>	US-5,827,666	10-27-1998	FINN et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS						
Examiner Initials			Publication Date	Name of Patentee or Publication Date Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Figures Appear	Т"
	BI	WO 98/04727	02-05-1998	Therion Biologics Corp. et al.		
						_
					1	

Examiner	Date		
Signature	Considered	1	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

				of albuman 1.	1 DANY 2006
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
			OSLIDE	Application Number	To be assigned
				I.A. Filing Date	1 Wyshort Off 2
				First Named Inventor	Dennis L. Panicali
			(יכיז	Art Unit	To be assigned
		Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	700953-53676

	_	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	AARTS, Wilhelmina M. et al.; Cancer Research; 62:5770-5777 (October 15, 2002)	
	C2	SCHLOM, Jeffrey et al.; Breast Cancer Research and Treatment; 38:27-39 (1996)	
	C3	SCHOLL, Susy et al.; Journal of Biomedicine and Biotechnology; 3:194-201 (2003)	
	C4	ZAJAC, P. et al.; Human Gene Therapy; 14:1497-1510 (November 1, 2003)	
	C5	GROSENBACH et al., Cancer Research, June 2001, vol. 61, 4497-4050	
	C6	GREINER et al., Cancer Research, December 2002, vol. 62, 6944-6951	

Examiner		•	Date	
Signature	l		Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.